Lv7
5000 积分 2023-11-10 加入
HyM2Surv: Hypergraph learning for cross-magnification and microbiome-attentive multimodal survival prediction
21天前
已完结
Distinct intratumoral microbiome of young-onset and average-onset colorectal cancer
21天前
已完结
Integrative analysis reveals intra-tumoral microbial enterotypes shape host transcriptomes in colorectal cancer
21天前
已完结
SlideChat is a multimodal generative artificial intelligence assistant for whole-slide computational pathology across cancer types
22天前
已完结
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
2个月前
已完结
Ensartinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
2个月前
已完结
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
2个月前
已完结
1787MO Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC)
2个月前
已完结
Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review
2个月前
已完结
Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
2个月前
已完结
皖公网安备34019202002308
